Hologic, Inc. (NASDAQ:HOLX) Q4 and Fiscal Year 2024 Report

Hologic, Inc. (NASDAQ:HOLX), a medical technology company, reported a strong performance in its fourth quarter and full fiscal year 2024. Total Q4 revenue reached $987.9 million with non-GAAP earnings per share (EPS) of $1.01, surpassing the company's earlier guidance.

For fiscal 2024, Hologic achieved $4.03 billion in revenue, with non-GAAP EPS of $4.08. Key growth drivers included an 9% growth in Molecular Diagnostics (excluding COVID) and strategic acquisitions.

Guidance for Fiscal 2025

Hologic anticipates Q1 revenue between $1.025 billion and $1.035 billion and full-year revenue between $4.15 billion and $4.20 billion, with EPS ranging from $4.25 to $4.35. The company is optimistic about growth, particularly in international markets, leveraging its product portfolio and M&A strategy.

Key Takeaways

• Q4 revenue was $987.9 million, with non-GAAP EPS of $1.01, beating guidance.
• Fiscal 2024 revenue was $4.03 billion, with non-GAAP EPS of $4.08.
• Molecular Diagnostics grew 9%.
• A $250 million accelerated share repurchase program was announced.
• Revenue from the Scalable business declined by 54.9% due to a shipping halt, expected to resume in Q1 2025.
• Fiscal 2025 guidance projects Q1 revenue of $1.025 billion to $1.035 billion and full-year revenue of $4.15 billion to $4.20 billion, with EPS between $4.25 and $4.35.
• The company anticipates 4% organic growth for full year 2025.

Company Outlook

• Hologic plans to drive future growth through its robust product portfolio and M&A strategy, aiming at international market penetration.
• The firm is poised to maintain growth and enhance its product pipeline in fiscal 2025.

Risks and Opportunities

Bearish Highlights
– The Scalable business faced a significant decline due to a temporary shipping halt.
– The Breast Health segment may see slower revenue in 2025 prior to a product launch.

Bullish Highlights
– Diagnostics revenue increased 6.2% in Q4, with Molecular Diagnostics up 9.1%.
– Breast Health and Surgical revenues grew by 6.2% and 5.4%, respectively.
– International business has expanded nearly 50% since 2019, indicating significant growth potential.

Performance and Market Position

Hologic's strong Q4 and fiscal 2024 performance reflects its solid market presence, with a market capitalization of $19.45 billion. Financial health is supported by moderate debt levels and a surplus of liquid assets, enabling growth initiatives.

Hologic's stock has shown a 21.92% total return over the past year, aligning with its optimistic fiscal 2025 outlook focused on international expansion.

Q&A Summary

During the earnings call, Hologic leaders discussed:
– A 4% expected revenue growth for fiscal 2025.
– International market sales projected to outpace domestic growth.
– Challenges posed by market competition for specific products and anticipated acquisitions that will enhance existing product offerings.

Overall, Hologic aims for continued growth and improved operational efficiency, focusing on international market opportunities and maintaining its leadership position within women’s health.

This article was generated with AI assistance and verified by an editor. For more details, see our T&C.